Future treatment for COPD: Targeting oxidative stress and its related signal

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 7, Issue 1, 2013, Pages 1-11

  Wada, Hiroo ^a   Takizawa, Hajime ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Arachidonic acid; COPD; Inflammation; Neutrophil; Oxidative stress

Indexed keywords

ARACHIDONIC ACID; ARFORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CIGARETTE SMOKE; CORTICOSTEROID; DAROTROPIUM BROMIDE; ENZYME INHIBITOR; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GARENOXACIN; GW 573719; INDACATEROL; INFLUENZA VACCINE; IPRATROPIUM BROMIDE; LEVOFLOXACIN; MOXIFLOXACIN; MUSCARINIC M3 RECEPTOR ANTAGONIST; MYELOPEROXIDASE INHIBITOR; OXYGEN; PHOSPHODIESTERASE IV; PNEUMOCOCCUS VACCINE; PROCATEROL; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILANTEROL;

AGING; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMMUNITY ACQUIRED PNEUMONIA; DIETARY INTAKE; DRUG EFFICACY; DRUG MECHANISM; ENVIRONMENTAL FACTOR; HUMAN; HYPOXIA; INFECTION; INFLAMMATION; INFLUENZA; LONG TERM CARE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY REHABILITATION; QUALITY OF LIFE; REVIEW; SMOKING CESSATION;

EID: 84874859293     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221313804004709     Document Type: Review

References (128)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349:1 498-504.
2. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-80.
3. American Thoracic Society: Standard for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S120.
4. National institute of healthy, National Heart, Lung and Blood Institute, Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseases. Publication Number 2701, 2001.
5. Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseases. (REVISED 2011) Publication Number 2701, 2011.
6. Japnese Respiratory Society: Guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease. Nihon Kokyuki Gakkai Zasshi 2009; (Suppl):1-137.
7. Beeh KM, Kornmann O, Buhl R, Culpitt SV Giembycz MA, Barnes PJ. Neutrophil chemotactic activity of sputum from patients with COPD: Role of interleukin 8 and leukotriene B4. Chest 2003; 123: 1240-7.
8. st century. Drugs 2003; 63: 1973-98.
9. Hasday JD, Bascom R, Costa JJ, Fitzgerald T, Dubin W. Bacterial endotoxin is an active component of cigarette smoke. Chest 1999; 115: 829-35.
10. Gebremichael A, Tullis K, Denison MS, Cheek JM, Pinkerton KE. Ah-receptor-dependent modulation of gene expression by aged and diluted sidestream cigarette smoke. Toxicol Appl Pharmacol 1996; 141: 76-83.
11. Kitamura M, Kasai A. Cigarette smoke as a trigger for the dioxin receptor-mediated signaling pathway. Cancer Lett 2007; 252: 184-94.
12. Jones DP, Go Y-M. Redox compartmentalization and cellular stress. Diabetes Obes Metab 2010;12 (Suppl 2):116-25.
13. Cantin AM. Cellular responses to cigarette smoke and oxidants. Proc Am Thrac Soc 2010; 7: 368-75.
14. Tudor RM, Yoshida T, Fijalkowka I, Biswal S, Petrache I. Role of lung maintenance program in the heterogeneity of lung destruction in emphysema. Proc Am Thorac Soc 2006; 3: 673-9.
15. Sies H. Oxidative stress. In: Sies H ed. Oxidative Stress. London: Academic Press, 1985;1-8.
16. Stanojkovic I, Kotur-Stevuljevic J, Milenkovic B, Spasic S, Vujic T, Stefanovic A, et al. Pulmonary function, oxidative stress and inflammatory markers in severe COPD exacerbation. Respir Med 2011; (Suppl105): S31-7.
17. Montaño M, Cisneros J, Ramírez-Venegas A, Pedraza-Chaverri J, Mercado D, Ramos C, et al. Malondialdehyde and superoxide dismutase correlate with FEV(1) in patients with COPD associated with wood smoke exposure and tobacco smoking. Inhal Toxicol 2010; 22: 868-74.
18. Kirkil G, Mahdi MM, Seckin D, Sahin K, Kucuk O. Antioxidant effect of zinc picolinate in patients with chronic obstructive pulmonary disease. Respir Med 2008; 102: 840-4.
19. Hant I, Kocabase A, Canacankatan N, Kuleci S, Seydaoglu G. Oxidant-antioxidant balance in patients with COPD. Lung 2006; 184: 51-5.
20. Kluchova Z Petraxova D, Jppa P, Dorkova and Tkacov R. The association between oxidative stress and obstructive lung impairment in patients with COPD. Physiol Res 2007; 56: 51-6.
21. Ceylan E, Kocyigit A, Gencer M, Aksoy N, Selek S. Increase DNA damage in patients with chronic obstructive pulmonary disease who had once smoked or been exposed to biomass. Respir Med 2006; 100: 1270-6.
22. Tug T, Karatas F, Terzi SM. Antioxidant vitamins and malonyldialdehyde levels in acute exacerbation and stable periods of patients with chronic obstructive pulmonary disease. Clin Invest Med 2005; 27: 123-8.
23. Wada H, Hagiwara S, Saitoh E, Ieki R, Okamura T, Ota T, et al. Increased oxidative stress in patients with chronic obstructive pulmonary disease (COPD) as measured by redox status of plasma coenzyme Q10. Pathophysiology 2006; 13: 29-33.
24. Calikoglu M, Unlu A, Tamer L, Ercan B, Bugadayci R, Atik U. The levels of serum vitamin C, malonyldialdehyde and erythrocyte reduced glutathione in chronic obstructive pulmonary disease and in healthy smokers. Clin Chem Lab Med 2002; 40: 1028-31.
25. Bartoli ML, Novelli F, Costa F, Malagrinò L, Melosini L, Bacci E, et al. Malondialdehyde in exhaled breath condensate as a marker of oxidative stress in different pulmonary diseases. Mediators Inflamm 2011; 2011: 891752.
26. Corradi M, Pignatti P, Manini P, Andreoli R, Goldoni M, Poppa M et al. Comparison between exhaled and sputum oxidative stress biomarkers in chronic airway inflammation. Eur Repir J 2004; 24: 1011-7.
27. Barnes PJ. Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009; 6: 693-6.
28. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967-76.
29. Barnes PJ. Future treatments for chronic obstructive pulmonary disease and its co-morbidities. Proc Am Thorac Soc 2008; 5: 857-64.
30. Hayashi R, Wada H, Ito K, Adcock IM. Effects of glucocorticoids on gene transcription. Eur J Pharmacol 2004; 500: 51-62.
31. Ito K, Caramori G, Lim S, Oates T, Chung KF, Barnes PJ, et al. Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 2002; 166: 392-6.
32. Cosío BG, Mann B, Ito K, Jazrawi E, Barnes PJ, Chung KF, et al. Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. Am J Respir Crit Care Med 2004; 170: 141-7.
33. Yang SR, Chida AS, Bauter MR, Shafiq N, Seweryniak K, Maggirwar SB, et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol 2006; 291: L46-57.
34. Wada H, Hagiwara S, Saitoh E, Ieki R, Yamamoto Y, Adcock IM, et al. Up-regulation of blood arachidonate (20:4) levels in patients with chronic obstructive pulmonary disease (COPD). Biomarkers 2012; [Epub ahead of print].
35. Kostikas K, Gaga M, Papatheodorou G, Karamanis T, Orphanidou D, Loukides S. Leukotriene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma. Chest 2005; 127: 1553-9.
36. Praticò D, Basili S, Vieri M, Cordova C, Violi F, Fitzgerald GA. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am J Respir Crit Care Med 1998; 158: 1709-14.
37. Pawliczak R, Huang XL, Nanavaty UB, Lawrence M, Madara P, Shelhamer JH. Oxidative stress induces arachidonate release from human lung cells through the epithelial growth factor receptor pathway. Am J Respir Cell Mol Biol 2002; 27: 722-31.
38. Asai K, Hirabayashi T, Houjou T, Uozumi N, Taguchi R, Shimizu T. Human group IVC phospholipase A2 (cPLA2gamma). Roles in the membrane remodeling and activation induced by oxidative stress. J Biol Chem 2003; 278: 8809-14.
39. Menzies D, Nair A, Williamson PA, Schembri S, Al-Khairalla MZ, Barnes M, et al. Respiratory symptoms, pulmonary function, and markers of inflammation among bar workers before and after a legislative ban on smoking in public places. JAMA 2006; 296: 1742-8.
40. Fukuchi Y. The aging lung and chronic obstructive pulmonary disease: Similarity and difference. Proc Am Thorac Soc 2009; 6: 570-2.
41. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009; 135: 173-80.
42. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. TORCH Clinical Endpoint Committee. Ascertainment of causespecific mortality in COPD: Operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62: 411-5.
43. Pageon H, Bakala H, Monnier VM, Asselineau D. Collagen glycation triggers the formation of aged skin in vitro. Eur. J. Dermatol 2007; 17: 12-20.
44. Wada H, Hagiwara S, Goto H, Yamamoto Y. The redox status of coenzyme Q10 associated to the chronological age. J Am Geriatrics Soc 2007; 55: 1141-2.
45. Nakamaru Y, Vuppusetty C, Wada H, Milne JC, Ito M, Rossios C, et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J 2009; 23: 2810-9.
46. Rajendrasozhan S, Yang WR, Kinnula VL, Rhaman I. SIRT1, an anti-inflammatory and anti-aging protein, is decrease in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 861-70.
47. Guarente L. Sirtuins, aging, and medicine. N Engl J Med 2011; 364: 2235-44.
48. Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908: 244-54.
49. Allen CL, and Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke 2009; 4: 461-70.
50. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: Therapeutic approaches. J Transl Med 2009; 7: 97.
51. Bartz RR, Piantadosi CA. Clinical review oxygen as a signaling molecule. Crit Care 2010; 14: 234.
52. Sethi S, Murphy TF. Infection in the pathogenesis and ourse of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-65.
53. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): A prespecified subgroup analysis of a randomized controlled trial. Lancet 2009; 374: 1171-8.
54. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, et al. Annual changes in pulmonary function and clinical phenotype in chronic obstructive pulmonary diseases. Am J Respir Crit Care Med 2012; 185: 44-52.
55. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 770-7.
56. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-53.
57. Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Ann Intern Med 1980; 93: 391-8.
58. Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681-6.
59. Fujimoto K, Yoshiike F, Yasuo M, Kitaguchi Y, Urushihata K, Kubo K, et al. Effects of bronchodilators on dynamic hyperinflation following hyperventilation in patients with COPD. Respirology 2007; 12: 93-9.
60. Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A. et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: Indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155-62.
61. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65: 473-9.
62. Berton DC, Reis M, Siqueira AC, Barroco AC, Takara LS, Bravo DM, et al. Effects of tiotropium and formoterol on dynamic hyper inflation and exercise endurance in COPD. Respir Med 2010; 104: 1288-96.
63. Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med 2012; 106: 91-101.
64. Tashkin DP, Donohue JF, Mahler DA, Huang H, Goodwin E, Schaefer K, et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med 2009; 103: 516-24.
65. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-89.
66. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 948-55.
67. Miravitlles M, Marín A, Monsó E, Vilà S, de la Roza C, Hervás R, et al. Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. Eur Respir J 2009; 34: 1066-71.
68. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: A randomised placebo-controlled trial. Lancet 2001; 358: 2020-5.
69. Lode H, Eller J, Linnhoff A, Ioanas M, Evaluation of Therapy-Free Interval in COPD Patients Study Group. Levofloxacin versus clarithromycin in COPD exacerbation: Focus on exacerbation-free interval. Eur Respir J 2004; 24: 947-53.
70. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2001; 365: 689-98.
71. Mikura S, Wada H, Higaki M, Yasutake T, Ishii H, Kamiya S, et al. Erythromycin prevents the pulmonary inflammation induced by exposure to cigarette smoke. Transl Res 2011; 158: 30-7.
72. Kam-Wah, T. Treatment of chronic obstructive pulmonary disease. GB2362101 (2001).
73. Churg A, Marshall CV, Sin DD, Bolton S, Zhou S, Thain K, et al. Late intervention with a myeloperoxidase inhibitor stops progression of experimental COPD. Am J Respir Crit Care Med 2012; 185: 34-43.
74. Yamamoto Y, Yamashita S. Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. Mol Aspects Med 1997; (Suppl18): S79-84.
75. Yamamoto Y, Yamashita S. Plasma ubiquinone to ubiquinol ratio in patients with hepatitis, cirrhosis, and hepatoma, and in patients treated with percutaneous transluminal coronary reperfusion. Biofactors 1999; 9: 241-6.
76. Yamamoto Y, Yamashita S, Fujisawa A, Kokura S, Yoshikawa T. Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem Biophys Res Commun 1998; 247: 166-70.
77. Sohmiya M, Tanaka M, Tak NW, Yanagisawa M, Tanino Y, Suzuki Y, et al. Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease. J Neurol Sci 2004; 223: 161-6.
78. Sohmiya M, Tanaka M, Suzuki Y, Tanino Y, Okamoto K, Yamamoto Y. An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. J Neurol Sci 2005; 228: 49-53.
79. Hara K, Yamashita S, Fujisawa A, Ishiwa S, Ogawa T, Yamamoto Y. Oxidative stress in newborn infants with and without asphyxia as measured by plasma antioxidants and free fatty acids. Biochem Biophys Res Commun 1999; 257: 244-8.
80. McMurray JJ, Dunselman P, Wedel H, Cleland JG, Lindberg M, Hjalmarson A, et al. CORONA Study Group. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: A pre-specified sub study of CORONA (controlled rosuvastatin multinational study in heart failure). J Am Coll Cardiol 2010; 56: 1196-204.
81. Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev 2009; (4): CD007435.
82. Liu J, Wang L, Zhan SY, Xia Y. Coenzyme Q10 for Parkinson's disease. Cochrane Database Syst Rev 2011; 12: CD008150.
83. Satta A, Grandi M, Landoni CV, Migliori GB, Spanevello A, Vocaturo G, et al. Effects of ubidecarenone in an exercise training program for patients with chronic obstructive pulmonary diseases. Clin Ther 1991; 13: 754-7.
84. Cazzola M, Centanni S, Boveri B, Di Marco F, Santus P, Matera MG, et al. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. Respiration 2001; 68: 452-9.
85. Celik P, Sakar A, Havlucu Y, Yuksel H, Turkdogan P, Yorgancioglu A. Short-term effects of montelukast in stable patients with moderate to severe COPD. Respir Med 2005; 99: 444-50.
86. Rubinstein I, Kumar B, and Schriever C. Long-term motelukast therapy in moderate to severe COPD-a preliminary observation. Respir Med 2004; 98: 134-8.
87. Grönke L, Beeh KM, Cameron R, Kornmann O, Beier J, Shaw M, et al. Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2008; 21: 409-17.
88. Hicks A, Goodnow R Jr, Cavallo G, Tannu SA, Ventre JD, Lavelle D, et al. Effects of LTB4 receptor antagonism on pulmonary inflammation in rodents and non-human primates. Prostaglandins Other Lipid Mediat 2010; 92: 33-43.
89. Bacani, G.M., Diego, B.D., Eugene, Y., Cheung, E.Y., Christa, C., Chrovian, C.C., Deng, X., Laurent, G., Grice, C. A., Kearney, A.M., Landry-Bayle, A. M., Lee-Dutra, A., Liang, J. T., Lochner, S., Mani, N. S., Santillán, A. Jr., Sappey, K., Sepassi, K., Tanis, V. M., Wickboldt, A. T., Wiener, J.J.M. Zinser, H. Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine as modulators of leukotriene A4 hydrolase. US7939527 (2011).
90. Dominique, R., Goodnow, R. A. Jr., Kowalczyk, A., Qiao, Q., Sidduri, A., Tilley, J.W. Leukotriene B4 inhibitors. WO2010108856 (2010).
91. Kumar, V.A., Sanjay, M., Abhijit, R., Raj, K.S. Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors. EP1834953 (2007).
92. Woodruff PG, Albert RK, Bailey WC, Casaburi R, Connett JE, Cooper JA Jr et al. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. COPD 2011; 8: 21-9.
93. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 2009; 49: 123-50.
94. Barnes PJ. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 2010; 19: 330-8.
95. Milara J, Navarro A, Almudever P, Lluch J, Morcillo EJ, Cortijo J. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages. Clin Exp Allergy 2011; 41: 535-46.
96. Brown DM, Hutchson L, Donaldson K, MacKenzie SJ, Dick CA, Stone V. The effect of oxidative stress on macrophages and lung epithelial cells: The role of phosphodiesterases 1 and 4. Toxicol Lett 2007; 168: 1-6.
97. Keshavarzian A, Mutlu E, Guzman JP, Forsyth C, Banan A. Phosphodiesterase 4 inhibitors and inflammatory bowel disease: Emerging therapies in inflammatory bowel disease. Expert Opin Investig Drugs 2007; 16: 1489-506.
98. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, et al. The preclinical pharmacology of roflumilast-selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010; 23: 235-56.
99. Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: Guarded optimism or wishful thinking? Br J Pharmacol 2008; 155: 288-290.
100. Barnes PJ. Frontrunners in novel pharmacotherapy of COPD. Curr Opin Pharmacol 2008; 8: 300-7.
101. Price D, Chisholm A, Ryan D, Crockett A, Jones R. The use of roflumilast in COPD: A primary care perspective. Prim Care Respir J 2010; 19: 342-51.
102. Giembycz MA, Field SK. Roflumilast: First phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther 2010; 4: 147-58.
103. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, et al. M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: Two randomised clinical trials. Lancet 2009; 374: 695-703.
104. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011; 163: 53-67.
105. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials. Lancet 2009; 374: 685-94.
106. Bateman ED, Rabe KF, Calverley PM, Goehring UM, Brose M, Bredenbröker D, et al. Roflumilast with long-acting β2-agonists for COPD: Influence of exacerbation history. Eur Respir J 2011; 38: 553-60.
107. Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res 2011; 12: 18.
108. Ito K, Caramori G, Adcock IM. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther 2007; 321: 1-8.
109. Marwick JA, Caramori G, Stevenson CS, Casolari P, Jazrawi E, Barnes PJ, et al. Inhibition of PI3K delta restores glucocorticoid function in smoking induced airway inflammation in mice. Am J Respir Cirt Care Med 2009; 179: 542-8
110. Yamaya M, Azuma A, Tanaka H, Takizawa H, Chida K, Taguchi Y, et al. Inhibitory effects of macrolide antibiotics on exacerbations and hospitalization in chronic obstructive pulmonary disease in Japan: A retrospective multicenter analysis. J Am Geriatr Soc 2008; 56: 1358-60.
111. Takizawa H. Novel strategies for the treatment of asthma. Recent Pat Inflamm Allergy Drug Discov 2007; 1: 13-9.
112. Desaki M, Okazaki H, Sunazuka T, Omura S, Yamamoto K, Takizawa H. Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: Possible role in the signaling pathway that regulates nuclear factor-kappaB activation. Antimicrob Agents Chemother 2004; 48: 1581-5.
113. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004; 117 (Suppl 9A): 5S-11S.
114. Nakanishi Y, Kobayashi D, Asano Y, Sakurai T, Kashimura M, Okuyama S, et al. Clarithromycin prevents smoke-induced emphysema in mice. Am J Respir Crit Care Med 2009; 179: 271-8.
115. Kellenberger, J.L., Dreier, J. New macrolides and their use. WO2011018510 (2011).
116. Napoletano, M., Moriggi, E., Mereu, A., Ornaghi, F., Morazzoni, G., Longoni, R., Riva, C., Pacchetti, L., Pellacini, F. Macrolide compounds endowed with anti-inflammatory activity. US20090054357 (2009).
117. Cheng C, Ho WE, Goh FY, Guan SP, Kong LR, Lai WQ, et al. Anti-malarial drug artesunate attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathway. PLoS One 2011; 6: e20932.
118. Mercado N, To Y, Ito K, Barnes PJ. Nortriptyline reverses corticosteroid insensitivity by inhibition of phosphoinositide-3-kinasesigma. J Pharmacol Exp Ther 2011; 337: 465-70.
119. To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, et al. Targeting phosphoinositide 3 kinase delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 897-904.
120. Rossios C, To Y, Osoata G, Ito M, Barnes PJ, Ito K. Corticosteroid insensitivity is reversed by formoterol via phosphorinositol 3 kinase inhibitor. Br J Pharmacol 2012; doi: 10.1111/j.1476-5381.2012.01864.x.
121. Harvey CJ, Thimmulappa RK, Sethi S, Kong X, Yarmus L, Brown RH, et al. Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. Sci Transl Med 2011; 3: 78ra32.
122. Moghaddam SJ, Barta P, Mirabolfathinejad SG, Ammar-Aouchiche Z, Garza NT, Vo TT, et al. Curcumin inhibits COPD-like airway inflammation and lung cancer progression in mice. Carcinogenesis 2009; 30: 1949-56.
123. Meja KK, Rajendrasozhan S, Adenuga D, Biswas SK, Sundar IK, Spooner G, et al. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC-2. Am J Respir Crit Care Med 2008; 39: 312-23.
124. Reddy NM, Suryanaraya V, Yates MS, Kleeberger SR, Hassoun PM, Yamamoto M, et al. The treterpenoid CDDO-Imidazolide confers potent protection against hyperoxic acute lung injury in mice. Am J Respir Crit Care Med 2009; 180: 867-74.
125. Ichikawa T, Li Jinqin, Meyer CJ, Janicki JS, Hannink M, Cui T. Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes. PLos One 2009; 4: e8391.
126. Malhotra D, Thimmulappa RK, Mercado N, Ito K, Kombairaju P, Kumar S, et al. Denitrosylation of HDAC2 by targeting Nrf restores glucocorticosteroid sensitivity in macrophages form COPD patients. J Clin Invest 2011; 121:4289-302.
127. Kumar V, Kumar S, Hassan M, Wu H, Thimmulappa RK, Kumar A, et al. Novel chalcone derivatives as potent Nrf-2 activators in mice and human lung epithelial cells. J Med Chem 2011; 54: 4147-59.
128. Camins A, Sureda FX, Junyent F, Verdaguer E, Folch J, Pelegri C, et al. Sirtuin activators: Designing molecules to extend life span. Biochim Biophys Acta 2010; 1799: 740-9.